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Mutated CTSF in adult-onset neuronal
ceroid lipofuscinosis and FTD
ABSTRACT
Objective: To investigate the molecular basis of a Belgian family with autosomal recessive adult-onset
neuronal ceroid lipofuscinosis (ANCLor Kufs disease [KD]) with pronounced frontal lobe involvement and
to expand the findings to a cohort of unrelated Belgian patients with frontotemporal dementia (FTD).
Methods: Genetic screening in the ANCL family and FTD cohort (n 5 461) was performed using
exome sequencing and targeted massive parallel resequencing.
Results: We identified a homozygous mutation (p.Ile404Thr) in the Cathepsin F (CTSF) gene
cosegregating in the ANCL family. No other mutations were found that could explain the disease
in this family. All 4 affected sibs developed motor symptoms and early-onset dementia with
prominent frontal features. Two of them evolved to akinetic mutism. Disease presentation
showed marked phenotypic variation with the onset ranging from 26 to 50 years. Myoclonic
epilepsy in one of the sibs was suggestive for KD type A, while epilepsy was not present in the
other sibs who presented with clinical features of KD type B. In a Belgian cohort of unrelated
patients with FTD, the same heterozygous p.Arg245His mutation was identified in 2 patients
who shared a common haplotype.
Conclusions: A homozygous CTSF mutation was identified in a recessive ANCL pedigree. In
contrast to the previous associations of CTSF with KD type B, our findings suggest that CTSF
genetic testing should also be considered in patients with KD type A as well as in early-onset
dementia with prominent frontal lobe and motor symptoms. Neurol Genet 2016;2:e102; doi:
10.1212/NXG.0000000000000102
GLOSSARY
ANCL 5 adult-onset neuronal ceroid lipofuscinosis; bv 5 behavioral variant; CTSF 5 cathepsin F; FTD 5 frontotemporal dementia;
KD 5 Kufs disease; NCL 5 neuronal ceroid lipofuscinosis; PSP 5 progressive supranuclear palsy; STR 5 short tandem repeat.
Neuronal ceroid lipofuscinoses (NCLs) are inherited, progressive, neurodegenerative, lyso-
somal storage diseases. Adult-onset NCLs (ANCLs), also known as Kufs disease (KD), are
rare and challenging to diagnose. In contrast to the childhood forms, which are all recessive
diseases, both recessive and dominant inherited forms occur in adults. Recessive ANCL has
been divided into 2 overlapping clinical subtypes presenting predominantly as (1) progressive
myoclonus epilepsy with dementia, ataxia, and late-onset pyramidal and extrapyramidal signs
(type A, CLN6 disease) or (2) progressive behavioral abnormalities and dementia which may
be associated with motor dysfunction, ataxia, extrapyramidal signs, and suprabulbar signs
(type B).1 Some ANCL families with autosomal dominant inheritance are referred to as
Parry disease.
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Molecular genetic studies have started to
unravel the underlying genetic defects in
ANCL. The first genes were reported in
2011, with the identification of mutations
in the CLN6 gene (CLN6)2 in KD type A
and mutations in DNAJC5 in some cases of
Parry disease (CLN4).1,3 Next, mutations in
cathepsin F (CTSF) were linked to KD type B
(CLN13).4,5 Still, several families and patients
with ANCL remain unresolved, indicating
that other genes are yet to be identified.
This study describes a Belgian ANCL family
with 4 affected sibs and unaffected parents.
Exome sequencing was used to pursue the causal
genetic defect, and case descriptions of the clini-
cal and neuropathologic features are provided.
Because of the overlap in clinical symptoms with
frontotemporal dementia (FTD), we additionally
examined a Belgian cohort of unrelated patients
with FTD for mutations in CTSF.
METHODS Study populations. The Belgian ANCL family
consisted of 5 sibs, 3 women, and 2 men, born to nonconsangui-
neous parents (figure 1A). A group of 1,177 neurologically
healthy Belgian research participants (mean age at inclusion:
66.46 13 years) was used as control cohort in the genetic screen
of the CTSF mutation identified in the ANCL family. A total
of 461 unrelated Belgian patients with FTD (mean onset age:
61.7 6 10.3 years) and a subset of 607 controls (mean age at
inclusion: 70.96 9.3 years) were used in the mutation screening
of all coding exons of CTSF.
Standard protocol approvals, registrations, and patient
consents. The clinical and genetic studies were approved by the
ethics committee of the respective hospitals and by the ethical
committee of the Antwerp University Hospital and University
of Antwerp, Belgium. Informed consent was obtained from all
participants.
Neuropathology and electron microscopy. The autopsied
brain of index patient II-2 was inspected by macroscopic and
Figure 1 Mutated CTSF in adult-onset neuronal ceroid lipofuscinosis and patients with frontotemporal dementia
(A) Pedigree of the recessive adult-onset neuronal ceroid lipofuscinosis (ANCL) Belgian family. The index patient or propositus (case II-2) is indicated by an
arrow. Participants whose exomes were sequenced are indicated with an asterisk. Current age, age at onset in case of patients, and age at death are indi-
cated in years. (B) Haplotype segregation in the ANCL pedigree. CTSF p.Ile404Thr carrier status and phased haplotypes using CTSF flanking short tandem
repeat (STR) markers are shown. The green haplotype indicates the maternal disease haplotype; yellow haplotype indicates the paternal inherited disease
haplotype. The blue and pink haplotypes carry the wild-type allele. (C) Cathepsin F (CTSF) protein with present and reported4,5 CTSF mutations associated
with recessive ANCL. Mutations are mapped to the primary structure of the CTSF protein indicating known functional domains. CTSF p.Ile404Thr homo-
zygous mutation identified in the Belgian family is indicated in red. CTSF p.Arg245His heterozygote mutation identified in 2 Belgian patients with fronto-
temporal dementia (FTD) is indicated in green. Reportedmutations are in black. Subscripts a and b indicate reported compound heterozygous mutation pairs.
(D) Sequence alignment of identified CTSF p.Arg245His and p.Ile404Thr mutations showing evolutionary conservation across species.
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microscopic examinations (figure 2) as well as by electron
microscopy (figure 3). Skin biopsies of patient II-2 and of his
affected brother II-5 (figure 3F) were also examined by electron
microscopy, respectively in 1993 and 2013.
Exome sequencing. Whole exome sequencing was performed in
patients II-1, II-2, II-5, the unaffected mother (I-2), and the
unaffected sib (II-4), using the SureSelect Human All Exon
V51UTR kit (Agilent Technologies, Santa Clara, CA) and
sequencing on a HiSeq 2000 (Illumina, San Diego, CA). Variants
with a predicted protein-modifying effect and genotypes consistent
with a recessive inheritance model were selected.
For mutation validation, segregation analysis, and testing of
controls, exon 10 of CTSF, comprising the p.Ile404Thr muta-
tion, was analyzed using Sanger sequencing in the family mem-
bers and in 1,177 Belgian control individuals.
In the ANCL family, the disease haplotype was determined
using a panel of 6 short tandem repeats (STRs) flanking CTSF
on both sides. In addition, allele sharing with 2 heterozygous
control carriers of the mutation found in the ANCL family was
analyzed.
Mutation screening of CTSF in patients with FTD and
control individuals. The 13 coding exons of CTSF were ampli-
fied in multiplex PCRs using the MASTR technology (http://
www.multiplicom.com) and sequenced on a MiSeq platform
(Illumina). Identified variants were validated by Sanger
sequencing.
In the 2 FTD patients with a heterozygous CTSF mutation,
allele sharing was analyzed using the same STR panel as in the
ANCL family.
Procedures. Procedures are detailed in the supplemental data
(appendix e-1 at Neurology.org/ng).
RESULTS The Belgian ANCL family. In this family
with unaffected parents, 4 of the 5 sibs developed ANCL
(figure 1A). The eldest sister (II-1), born in 1948, is still
alive and has no children. She developed generalized
myoclonic epileptic seizures at the age of 35 years, fol-
lowed by extrapyramidal symptoms and cognitive dis-
turbances 7 and 15 years later, respectively. CT scan of
the brain at the age of 35 revealed moderate cortical
and subcortical atrophy, too pronounced for
her age. Brain MRI at the age of 62 showed
generalized cortical-subcortical atrophy. In-depth
neuropsychological investigations were consistent with
a diagnosis of behavioral variant (bv) FTD. The eldest
brother (II-2; propositus) was born in 1952 and remained
childless. At the age of 26 years, he had developed
progressive motor speech problems. MRI of the brain
revealed mild generalized cortical-subcortical atrophy. At
the age of 54, his condition progressively worsened, with
severe motor, cognitive, and behavioral decline, consistent
with a diagnosis of bvFTD. Repeat MRI of brain
demonstrated generalized cortical-subcortical atrophy. In
the final stage, he developed akinetic mutism and died in
2012 at the age of 60. The second daughter (II-3) was
born in 1953. At the age of 30 years, she presented with
progressive apathy and behavioral, cognitive, and affective
disturbances. Brain CT disclosed severe generalized
cortical-subcortical atrophy. She died in 2007 at the age
of 54, after a long period of progressive behavioral and
cognitive disturbances resulting in severe dementia
(bvFTD) and akinetic mutism. She was the mother of
2 healthy children. The youngest daughter (II-4), born
in 1960, is healthy and the mother of 2 healthy
children. The youngest brother (II-5) was born in
1962 and has 2 healthy children. At the age of 50,
he developed right-sided tremor, motor speech
problems, general slowness, and feelings of anxiety.
Neuropsychological testing disclosed a general
cognitive decline, with prominent frontal lobe
involvement. MRI of the brain showed marked
generalized cortical-subcortical atrophy and a cyst of
the choroid plexus in the left lateral ventricle. The
mother of the 5 sibs was born in 1925 and is still
alive at age 90. Their father, born in 1921, died at
the age of 89.
Neuropathology and electron microscopy of the ANCL
family. Autopsy was performed on the brain of patient
II-2, which weighed 956 g. Macroscopic examination
revealed atrophy of the different lobes and
Figure 2 Light microscopy images of brain autopsy case II-2
Frontal cortex (area 8). (A) Swollen neuronal perikarya and the proximal part of the axons (ar-
rows). (B) Age-matched control case. (C) Dilated proximal axons filled with lipopigmentary
granules (arrows). (D) Similar picture showing immunoreactivity for cathepsin D (arrows).
(E) Autofluorescence of the lipopigmentary granules. (F) Periodic acid-Schiff positivity of
the stored granules (arrows). Paraffin sections; A and C: Klüver-Barrera staining, B: cresyl
violet, D: antibody against cathepsin D, E: autofluorescence, F: Periodic acid-Schiff method;
scale 5 50 mm.
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dilation of the ventricular system. Microscopic
examination of the frontal, parietal, temporal, and
occipital neocortices showed generalized signs of
neuronal storage of a yellowish pigment, more
evident in the large pyramidal cells of the third
cortical layer but also in the Betz neurons of the
fifth cortical layer at the level of the precentral
gyrus. The granular storage was noted in the
perikaryon and could be followed in the proximal
part of the axon (figure 2, A and C). Sometimes,
the axon was enlarged after the axonal hillock. The
storage material was autofluorescent (figure 2E),
yellowish on cresyl violet and hematoxylin and
eosin stains, deep blue on Klüver-Barrera stain,
and strongly periodic acid-Schiff positive (figure
2F). AT8 (against hyperphosphorylated tau)
elicited a moderate amount of neurofibrillary
tangles and sparse neuritic threads in the
hippocampus and parahippocampal structures.
The presence of these findings had no clinical
relevance. TDP-43 immunohistochemistry did
not show any abnormalities. Cathepsin D staining
showed lipopigmentary granules (figure 2D). Other
immunohistochemical stains were negative.
Electron microscopic examination of the brain of
patient II-2 confirmed the intraneuronal storage of
polymorphic lipofuscin-like inclusions (diameter:
1–2mm) with granular components displaying distinc-
tive features (figure 3A). At higher magnifications,
densely packed short lamellar profiles, coarser granular
components (figure 3B), and lipid droplets as well as
lamellar complexes (figure 3C) and few fingerprints (fig-
ure 3D) were seen. These inclusions were mostly differ-
ent from the classical lipofuscin (figure 3E). Similar but
large coalescing inclusions were present in glial and mi-
croglial cells. Numerous polymorphic inclusions reveal-
ing coarse and densified granular subunits associated
with lipid droplets were observed in Golgi- or basket-
like cells. Glial cells and granule cells showed compound
lipofuscin-like deposits with granular subunits.
Sporadic granular lipopigments with osmiophilic
granules in Schwann cells as well as unmyelinated
Figure 3 Electron microscopy images of brain autopsy case II-2
(A) Frontal cortex. Intraneuronal storage of lipofuscin-like inclusions. Magnification: 35,750. (B) Occipital cortex. Neuronal
inclusion showing a granular pattern and densely packed short lamellar profiles, coarser granular compounds, and lipid
droplets. Magnification: 341,000. (C) Nucleus dorsomedialis of the thalamus. Intraneuronal intermingled granular and
lamellar complexes. Magnification: 327,000. (D) Temporal cortex. Predominance of fingerprints in a neuronal inclusion.
Magnification: 352,500. (E) Brain biopsy of a 34-year-old female patient without neuronal ceroid lipofuscinosis (control).
Intraneuronal classical lipofuscin. Magnification: 341,000. (F) Electron microscopic examination of skin biopsy case II-5.
Lipofuscin-like inclusion with an uncommon heterogeneous pattern in an endothelial cell of a blood vessel. Magnification:
327,000. Scale 5 1 mm.
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dystrophic axons were observed in the skin biopsy of
patient II-2, while lipofuscin-like inclusions with an
uncommon heterogeneous pattern were detected in ec-
crine sweat glands and blood vessels (figure 3F) of
patient II-5.
A more detailed description of the neuropathology
and electron microscopic examination can be found
in the supplemental data.
Identification of the causal gene defect in the ANCL
family. Analysis of the exomes identified only one rare
coding variant that was consistent with a recessive
mode of inheritance. The variant predicted a missense
mutation p.Ile404Thr in the CTSF gene and was
found homozygous in all affected sibs and heterozy-
gous in the unaffected mother and unaffected daugh-
ter (figure 1B). Segregation analysis with a panel of
flanking STR markers demonstrated that the CTSF
p.Ile404Thr mutation was inherited on 2 different
haplotypes and, as such, confirmed that the parents
were not consanguineous (figure 1B). The presence of
the p.Ile404Thr mutation was tested in an extended
cohort of 1,177 Belgian control persons. No homo-
zygous carriers were found; however, p.Ile404Thr
was identified in the heterozygous state in 2 control
individuals, a 76-year-old man and a 67-year-
old woman. Inspection of their STR genotypes was
suggestive of a common haplotype with the paternal-
inherited disease haplotype (figure 1B, yellow
haplotype) of the ANCL family.
Genetic screening of CTSF in patients with FTD. Because
the neurocognitive profile of the ANCL family was
marked by prominent frontal lobe features evolving
to severe FTD with akinetic mutism at the end stage
of the disease in 2 sibs, the identified causal CTSF gene
was further tested for mutations in 461 unrelated Bel-
gian patients with FTD. We detected 1 heterozygote
mutation, p.Arg245His, in 2 patients (0.4%), which
was absent in the control cohort (figure 1C).
Mapping of the mutations on the CTSF protein. The
CTSF gene encodes a lysosomal cysteine protease,
CTSF, that belongs to the peptidase C1 family and is
believed to participate in the intracellular degradation
and turnover of proteins. CTSF is a 484 amino acid
protein with 2 known functional domains: a peptidase
inhibitor I29 domain and a peptidase C1 domain (figure
1C). In line with the majority of the reported CTSF
mutations, the p.Ile404Thr missense mutation maps to
the peptidase C1 domain near the C-terminal end of the
protein. In contrast, the p.Arg245His mutations fall
outside the known functional domains, yet flanking to
the inhibitor I29 domain. Both the p.Ile404Thr and the
p.Arg245His mutations affect conserved residues,
although for the latter, in mice, a His-residue is
present at the homologous position (figure 1D).
Clinical presentation of the FTD carriers of CTSF
p.Arg245His.One of the FTD patients with the hetero-
zygote p.Arg245His mutation developed signs of
bvFTD at the age of 65 years, marked by irritability,
socially inappropriate behavior, and verbal disinhibi-
tion. He also suffered from severe balance problems
causing repetitive falling, nocturnal myoclonus, dysar-
thria, mild word-finding difficulties, and a mild
asymmetrical extrapyramidal syndrome. At age 67, he
had developed constructional apraxia, dysphagia, and
impaired vertical eye movements. MRI of the brain
showed atrophy of the midbrain with a hummingbird
sign, compatible with progressive supranuclear palsy
(PSP). No clear family history was reported.
The second carrier developed memory problems at
the age of 76. She had 1 sister with unspecified demen-
tia, developed at the age of 75. The patient later devel-
oped slowness, balance problems with repeated falling,
inappropriate and compulsive behavior, incontinence,
echolalia, dysarthria, and extrapyramidal signs with
a vertical gaze palsy. At the age of 81, she evolved to
a state of akinetic mutism with swallowing problems.
Her MRI results also showed a hummingbird sign,
as in PSP, and a presynaptic dopaminergic degenera-
tion on dopamine transporter imaging.
There was no direct evidence for relatedness between
the two p.Arg245His carriers; however, STR genotyp-
ing flanking the mutation was indicative of a common
disease haplotype, suggesting a common founder.
DISCUSSION The present study investigated a reces-
sive kindred with a complex neurobehavioral syn-
drome characterized by progressive adult-onset
bvFTD, motor disturbances, and in 1 patient,
myoclonic epilepsy. Close clinical follow-up over
many years and neuropathologic examination of the
propositus (case II-2) ultimately pointed to the
diagnosis of recessive ANCL or KD.
Exome sequencing identified a cosegregating mis-
sense mutation in the CTSF gene, p.Ile404Thr. This
variant was the only homozygous variant shared
between all affected sibs and was heterozygote in
the unaffected relatives. Although all patients in the
family were homozygous for the same gene defect,
there was a remarkable variability in their phenotypic
expression, particularly early in the disease course,
with onset ages of presenting symptoms ranging from
26 years in case II-2 to 50 years in case II-5. In cases
II-2, II-3, and II-5, clinical features were most con-
sistent with KD type B and epilepsy was absent.
However, myoclonic epilepsy in case II-1 was sugges-
tive of KD type A. This observation is of interest
because CTSF homozygous mutations have, thus
far, been exclusively linked to KD type B. Alterna-
tively, the epilepsy phenotype in case II-1 might be
unrelated to the CTSF mutation and concurred by
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coincidence. Contrary to expectations, there was no
evidence for consanguinity in the parents who were
both of Belgian origin. Indeed, haplotype segregation
analysis confirmed that CTSF p.Ile404Thr mutation
occurred at least twice on 2 different haplotypes. This
is in line with the observation of the same mutation in
the heterozygote state in 2 unrelated Belgian control
persons (2/1,177, or 0.2%). In the 2 controls, allele-
sharing analysis was suggestive of a common haplotype
with the paternal haplotype observed in the family,
indicating that this CTSF disease haplotype is relatively
more common in the Belgian population.
Because of a constellation of pronounced behavioral,
cognitive, and motor features in the patients of the KD
family, it was hypothesized that mutations in CTSFmay
mimic an FTD phenotype. Analyses of a large set of
unrelated Belgian patients with FTD did not reveal
the same p.Ile404Thr mutation. However, another
mutation, p.Arg245His, was found in the heterozygous
state in 2 patients with FTD. It is not clear how hetero-
zygous mutations in a recessive gene such as CTSF may
lead to disease, although this may be explained by clinical
heterogeneity or pleiotropy where homozygous muta-
tions lead to a more severe phenotype with earlier onset
and heterozygous mutations of the same gene lead to
another (related) phenotype with later onset. Indeed, the
homozygous p.Ile404Thr carriers in the KD family
developed first symptoms in their 30s, whereas the 2
heterozygous p.Arg245His FTD carriers were diagnosed
at ages 65 and 76 years, respectively. Furthermore, it is
remarkable that both patients with FTD developed
a PSP phenotype with typical hummingbird sign on
brain MRI and, in addition to showing comparable
disease presentations, also showed interesting common-
alities with the patients of the KD family, including
balance problems, dysarthria, and extrapyramidal symp-
toms. Also the patients with FTD carried the heterozy-
gous p.Arg245His on the same haplotype, further
favoring a role in disease causation. Nevertheless, this
observation will need confirmation in independent
FTD cohorts before we can decide that heterozygous
CTSF mutations are causally associated with FTD.
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